|Application ||WB, IHC-P, E|
|Calculated MW||33275 Da|
|Other Names||Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, CD274, CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1, PDL-1|
|Target/Specificity||Recombinant anti-PD-L1 monoclonal antibody recognizes endogenous levels of total PD-L1 protein.|
|Format||Purified recombination monoclonal antibody supplied in PBS with 0.05% (W/V) sodium azide, and 0.05% BSA. This antibody is purified through a protein A column.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Recombinant PD-L1 antibody [AC37] is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).|
|Cellular Location||Cell membrane; Single-pass type I membrane protein. Early endosome membrane; Single-pass type I membrane protein. Recycling endosome membrane; Single-pass type I membrane protein. Note=Associates with CMTM6 at recycling endosomes, where it is protected from being targeted for lysosomal degradation. [Isoform 2]: Endomembrane system; Single-pass type I membrane protein|
|Tissue Location||Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Programmed cell death 1 ligand 1 (PD-L1, B7-H1, CD274) is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. The PD-L1 ligand binds the PD-1 transmembrane receptor and inhibits T cell activation. PD-L1 was discovered following a search for novel B7 protein homologs and was later shown to be expressed by antigen presenting cells, activated T cells, and tissues including placenta, heart, and lung. Similar in structure to related B7 family members, PD-L1 protein contains extracellular IgV and IgC domains and a short, cytoplasmic region. Research studies demonstrate that PD-L1 is expressed in several tumor types, including melanoma, ovary, colon, lung, breast, and renal cell carcinomas. Expression of PD-L1 in cancer is associated with tumor-infiltrating lymphocytes, which mediate PD-L1 expression through the release of interferon gamma. Additional research links PD-L1 expression to cancers associated with viral infections. Involved in the costimulatory signal, essential for T- cell proliferation and production of IL10 and IFNG, in an IL2- dependent and a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation and cytokine production.
Dong H.,et al.Nat. Med. 5:1365-1369(1999).
Freeman G.J.,et al.J. Exp. Med. 192:1027-1034(2000).
He X.-H.,et al.Acta Pharmacol. Sin. 26:462-468(2005).
Chi X.-Y.,et al.Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases.
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Dong, H. et al. (1999) Nat Med 5, 1365-9.
Freeman, G.J. et al. (2000) J Exp Med 192, 1027-34.
Liang, S.C. et al. (2003) Eur J Immunol 33, 2706-16.
Dong, H. et al. (2002) Nat Med 8, 793-800.
Thompson, R.H. et al. (2006) Cancer Res 66, 3381-5.
Pardoll, D.M. (2012) Nat Rev Cancer 12, 252-64.
Taube, J.M. et al. (2012) Sci Transl Med 4, 127ra37.
Lyford-Pike, S. et al. (2013) Cancer Res 73, 1733-41.
Chen, B.J. et al. (2013) Clin Cancer Res 19, 3462-73.
Wimberly, H. et al. (2014) Cancer Immunol Res , .
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.